Day: September 20, 2026

Moderna’s norovirus vaccine candidate mRNA-1403 has reached a critical milestone with phase 2 clinical trial results demonstrating meaningful protection against norovirus gastroenteritis. The vaccine leverages mRNA technology to encode virus-like particle antigens covering several norovirus genotypes, including the predominant GII.4 strain responsible for most outbreaks globally. The trial …